PLSH · Panacea Life Sciences Holdings, Inc.
$0.07
-0.01 (-14.71%)
At close · Sep 17
Going-concern doubt
— flagged May 6, 2024
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.”View the 10-Q filed May 6, 2024
Market Cap
$1.76M
Shares
17.65M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.07
Open$0.07
Day$0.07–0.07
52W close$0.03–0.14
Avg vol 30d20K
Short int8K · 0.0% float · 1.8d
Short vol16%
DataApr 2022–Sep 2026
Filing10-Q · May 6
Up next
filed May 6, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.76M
Trailing 12 months
Net income (TTM)
−$7.67M
Trailing 12 months
Revenue growth YoY
+55.9%
Year over year
Operating margin
-192.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.2%
Year over year · more shares
Price change (1Y)
+37.1%
Trailing year
Short interest
0.0%
Latest settlement · 1.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
+2%
above
RSI (14)
44
neutral
MACD trend
Negative
52-week position
41%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+39%
trailing
YTD return
+45%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.05% of float · ▲ +30.0% MoM · 1.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
29
low risk · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
Gross margin
49%
expanding
EPS growth
+23%
Y/Y
Free cash flow
$-1.6M
Balance sheet
$251.1K
net debt
Quant / Vol
risk profile
Volatility
453%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
19.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
41%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.05% of float · ▲ +30.0% MoM · 1.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 41%
Range high $0
vs 200-day avg +25%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLSH
this stock
Panacea Life Sciences Holdings, Inc.
|
$1.76M | +45.0% | +11.7% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$59.80B | +22.2% | — | — | 0.1% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.49B | +25.6% | +4.3% | 64.0 | 3.2% |
|
GALDY
Galderma Group AG/ADR
|
$44.48B | -8.0% | — | — | 0.0% |
|
HLN
Haleon plc
|
$41.16B | -7.4% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
1
- % held
- 0.0%
- Net QoQ
- -735 sh
- Top holder
- Castleview Partners, LLC
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLSH | -26.6% | -3.3% | +38.6% | -27.5% | +45.0% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | -27.3% | -2.5% | +20.4% | -26.9% | +33.2% |